Method for Identification of Inhibitors of Primary Nucleation of Amyloid-Beta Aggregation

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides a novel, efficient method to identify inhibitors that block the very early stages (primary nucleation) of amyloid-beta aggregation—a key process in the development of Alzheimer's disease. The method uses specially constructed amyloid-beta dimers (two monomers linked by a flexible peptide linker), which significantly accelerate aggregation, allowing for the fast and clear testing of potential inhibiting substances. The invention further describes compositions, linkers, and kits to facilitate this assay, as well as the use of the approach for other protein aggregation diseases.

Use CasesContent extracted from patent full text and abstract with AI.

• Screening pharmaceutical compounds for their ability to inhibit the primary nucleation of amyloid-beta aggregation (for Alzheimer's disease drug discovery).
• High-throughput testing of chemical libraries to find new candidates for Alzheimer's therapeutics.
• Evaluation of antibodies, peptides, or small molecules designed to block amyloid-beta aggregation at the earliest steps.
• Research into other protein misfolding diseases (such as Parkinson's or Huntington's) by adapting the method to other aggregation-prone proteins.
• Use in diagnostic laboratories to rapidly and reproducibly test the efficacy of potential aggregation inhibitors.

BenefitsContent extracted from patent full text and abstract with AI.

• Greatly reduces assay time by eliminating the lag phase in amyloid-beta aggregation, allowing for rapid screening.
• Requires less material—lower amounts of peptide are needed, making the method more cost-effective.
• Enables clearer attribution of inhibitor activity specifically to the primary nucleation process, thus improving understanding and selectivity of drug candidates.
• Versatile: can be adapted to different amyloid-beta species and potentially to other protein aggregation diseases.
• Amenable to automation and high-throughput formats (such as multiwell microtiter plates), broadening scalability for research and pharmaceutical use.
• More reliable differentiation between actual inhibitors of early aggregation and those affecting other aggregation steps.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a method for identifying inhibitors of the primary nucleation of amyloid-beta aggregation, comprising the following steps: a) A-beta species is provided in a buffer; b) the amyloid-beta aggregation is determined. The method is characterised in that c) two A-beta monomer units with a linker arranged between the A-beta monomers is selected as the A-beta species. Also disclosed are a linker used for that purpose, a kit and the uses thereof.